Myrexis appoints CEO, CFO and shakes up pipeline
This article was originally published in Scrip
Executive Summary
Myrexis, a biotech company developing small molecule compounds with novel chemical structures and distinct mechanisms of action, has decided to keep its interim president and CEO, Robert Lollini, in place as permanent CEO and a member of the board. Mr Lollini was also previously the company's CFO, a role which has now been filled by Andrea Kendell. Mr Lollini joined Myrexis in 2009 from Iomed, and Ms Kendell, who previously served at Moog Medical Devices Group, was most recently Myrexis' vice-president of finance and human resources.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.